Illicit use of androgenic anabolic steroids (AAS) is a known problem amongst certain groups including body builders and other athletes. Use of these drugs is thought to be high in some areas of South Wales. A number of adverse effects have been associated with use of AAS including the development of hepatic adenomas. There have been a handful of rare cases of the development of hepatocellular carcinoma following AAS use. We report two such cases presenting to the same surgical centre in South Wales within six months. We do this with reference to data from Public Health Wales, including the Harm Reduction Wales Needle and Syringe provision report, which indicate a particularly high rate of use of AAS in the surrounding area. We believe these cases are important from the public health point of view. They demonstrate a rare and not widely known about, but potentially fatal adverse effect of AAS, now becoming prevalent with the high use of these drugs. This is important for doctors to be aware of, but also could form the focus of a public health campaign targeted at AAS users. 
INTRODUCTION
Illicit use of androgenic anabolic steroids (AAS) is a known problem amongst some groups, including body builders and other athletes. The full extent of use of these drugs is not clear, due to limited studies. 1 However use of AAS is suspected to be high in some areas of South
Wales. 2 The Harm Reduction Database Wales: Needle and syringe provision 2015-16 report stated that of the 17,161
individuals accessing needle and syringe provision across Wales; 8,375 (48%) were primary Image and Performance
Enhancing Drug (IPED) users, this category of substances includes AAS. 3 Here we report of two cases of hepatocellular carcinoma (HCC) developing in young men in South Wales over the past 6 months. Many adverse effects of AAS have been documented. The development of liver cell adenomas is well known. However, there are only very few reports of HCC in patients using AAS. 4 We feel that a campaign to highlight this potentially lethal complication of AAS use may deter young persons from engaging in this activity. is a rare one, its seriousness is such that it should be considered when thinking about the harmful effects of these drugs within the population groups using them. The cases highlight the need not only for physicians to be aware of this adverse effect, but for wider publicity amongst populations who are using anabolic steroids. There may be need for a targeted public health campaign to raise further awareness of adverse effects of anabolic steroids, including the development of HCC.
CASE

